NEW YORK (GenomeWeb News) – Akrivis Technologies today said that it has inked an agreement with United States Biological to co-develop, manufacture, and sell research products based on Akrivis' Z-Tect technology.

The Z-Tect technology is a nanotechnology-based technique for detecting unusually low levels of protein and molecular targets. According to the firms, the technology has "ultra-low limits of detection several thousand fold lower than currently achievable," and will make it possible to "vastly improve the early detection of cancer biomarkers in vitro."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease. 

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.